You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 19, 2024

Claims for Patent: 10,842,751

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,842,751

Title:	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Abstract:	The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
Inventor(s):	Panmai; Santipharp (Cranford, NJ), Tatavarti; Aditya (Chalfont, PA), Farrington; Andrew M. (Collegeville, PA), Biyyala; Varsha (Somerset, NJ), Allain; Leonardo R. (Lansdale, PA), Nefliu; Marcela (Schwenksville, PA), Klinzing; Gerard R. (Wilmington, DE), Ren; Jie (Chalfont, PA), Lamm; Matthew (Morristown, NJ)
Assignee:	MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:	16/791,398
Patent Claims:	1. A tablet comprising a first layer comprising an amorphous dispersion formulation of doravirine, and a second layer comprising lamivudine and tenofovir disoproxil fumarate. 2. The tablet of claim 1 wherein the first layer further comprises a polymer. 3. The tablet of claim 2 wherein the polymer is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, polyvinylpyrrolidinone and polyvinylpyrrolidinone-polyvinylacetate copolymers. 4. The tablet of claim 3 wherein the polymer is hydroxypropyl methyl cellulose acetate succinate. 5. The tablet of claim 1 wherein the first layer further comprises microcrystalline cellulose. 6. The tablet of claim 1 wherein the first layer further comprises croscarmellose sodium. 7. The tablet of claim 1 wherein the second layer further comprises microcrystalline cellulose. 8. The tablet of claim 1 further comprising a film coat. 9. The tablet of claim 1 comprising 50 mg of doravirine, 150 mg of lamivudine and 150 mg of tenofovir disoproxil fumarate. 10. The tablet of claim 1 comprising 100 mg of doravirine, 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate. 11. A tablet comprising (i) a first layer comprising an amorphous dispersion formulation of doravirine, hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, and croscarmellose sodium, and (ii) a second layer comprising lamivudine, tenofovir disoproxil fumarate and microcrystalline cellulose.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.